#WLC25
LightNews LightNews
paulalagan.bsky.social
Truly wonderful and inspirational day representing #AFBI at the Women’s Leadership Conference #WLC25 @AFBI_NI @IoDNI
March 7, 2025 at 6:07 PM
onclive.bsky.social
We have landed in sunny Hollywood, Florida for the 22nd Annual Winter Lung Cancer Conference! Follow along on our site for exclusive #lcsm insights all weekend! #gotoPER #WLC25
www.onclive.com/conference/w...
January 31, 2025 at 3:58 PM
onclive.bsky.social
Next-Generation Sequencing Data Inform IO Treatment Sequencing in NSCLC #WLC25 #gotoPER #lcsm www.onclive.com/view/next-ge...
Next-Generation Sequencing Data Inform IO Treatment Sequencing in NSCLC
KEAP1 and STK11 have emerged as potential biomarkers of response to immuno-oncology combinations in frontline NSCLC.
www.onclive.com
February 3, 2025 at 10:34 PM
onclive.bsky.social
Thanks to Balazs Halmos, MD, and Susan Scott, MD, for interviewing with us about their #WLC25 Medical Crossfire debate on treatment selection in EGFR-mutant NSCLC! Check back on our site for their insights! @hopkinsmedicine.bsky.social #gotoPER #lcsm
www.onclive.com/conference/w...
February 2, 2025 at 6:14 PM
rielymd.bsky.social
PER’s Winter Lung meeting is coming up at the end of the month, in Hollywood, Florida. Lots of great speakers. Register today for FREE using RIELY as a discount code! bit.ly/3CS06Gf #gotoPER #WLC25 #lungcancer #winterlung
January 9, 2025 at 7:05 PM
onclive.bsky.social
A huge thanks to @benlevylungdoc.bsky.social, of @hopkinsmedicine.bsky.social, for stopping by during #WLC25 to talk all things ADCs in lung cancer! See our site for ADC insights and more! #gotoPER #lcsm
www.onclive.com/conference/w...
February 2, 2025 at 3:14 PM
onclive.bsky.social
Thank you to Julie Brahmer, MD, one of the #WLC25 meeting chairs, for joining us for an interview about highlights from the meeting and future advances in lung oncology! See our site for more conference insights! @hopkinsmedicine.bsky.social #gotoPER #lcsm
www.onclive.com/conference/w...
February 2, 2025 at 2:54 PM
onclive.bsky.social
Day 2 of the 22nd Annual Winter Lung Cancer Conference is here! With a view like this, who wouldn't want to soak up the latest lung cancer insights? Check out our site throughout the day for exclusive meeting updates! #gotoPER #WLC25 #lcsm
www.onclive.com/conference/w...
February 1, 2025 at 3:42 PM
onclive.bsky.social
Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized
#gotoPER #WLC25 #LCSM
www.onclive.com/view/targete...
Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized
The variety of nonclassical EGFR mutations in NSCLC necessitates the development of unique treatment strategies based on individual mutational profiles.
www.onclive.com
February 4, 2025 at 7:04 PM
onclive.bsky.social
Corey Langer, MD discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm. @pennmedicine.bsky.social #gotoPER #WLC25 #lcsm
www.onclive.com/view/dr-lang...
Dr Langer on the Evolution of Adjuvant Immunotherapy in NSCLC
Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.
www.onclive.com
February 1, 2025 at 1:44 AM
onclive.bsky.social
Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer. @benlevylungdoc.bsky.social @hopkinsmedicine.bsky.social #gotoPER #WLC25 #lcsm
www.onclive.com/view/dr-levy...
Dr Levy on the Development and Clinical Use of ADCs in NSCLC
Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer.
www.onclive.com
February 2, 2025 at 7:41 PM
onclive.bsky.social
Tarek Mekhail, MD, MSc, FRCSI, FRCSEd, discusses a case study of a patient with early-stage, nonmetastatic lung adenocarcinoma. #gotoPER #WLC25 #lcsm
www.onclive.com/view/dr-mekh...
Dr Mekhail on a Case Study of Early-Stage, Nonmetastatic Lung Cancer
Tarek Mekhail, MD, MSc, FRCSI, FRCSEd, discusses a case study of a patient with early-stage, nonmetastatic lung adenocarcinoma.
www.onclive.com
February 2, 2025 at 8:17 PM
onclive.bsky.social
Thank you to Dr Tarek Mekhail for speaking with us during #WLC25 about lung cancer case studies! Check out our site for more from the meeting! #gotoPER #lcsm
www.onclive.com/conference/w...
February 2, 2025 at 3:20 PM
onclive.bsky.social
The third and final day of #WLC25 is here! Stay tuned to see how the meeting wraps up, and follow along on our site as we share more KOL #lcsm insights from the meeting over the next few days! #gotoPER
www.onclive.com/conference/w...
February 2, 2025 at 2:49 PM
onclive.bsky.social
Shields Spotlights Lessons Learned in Limited-Stage SCLC and Areas Ripe for Further Research #WLC25 #gotoPER #lcsm www.onclive.com/view/shields...
Shields Spotlights Lessons Learned in Limited-Stage SCLC and Areas Ripe for Further Research
Misty Shields, MD, PhD, provides a comprehensive overview of key updates in. the management of limited-stage small cell lung cancer.
www.onclive.com
February 2, 2025 at 1:45 PM
onclive.bsky.social
Russell Hales, MD, discusses clinical data that challenge the use of post-operative radiotherapy in patients with non–small cell lung cancer. #gotoPER #WLC25 #lcsm
www.onclive.com/view/dr-hale...
February 2, 2025 at 2:16 AM
onclive.bsky.social
Estelamari Rodriguez, MD, MPH, discusses a case study of a patient with non–small cell lung cancer harboring an EGFR L858R mutation and a TP53 mutation. @latinamd.bsky.social #gotoPER #WLC25 #lcsm
www.onclive.com/view/dr-rodr...
Dr Rodriguez on a Case Study of EGFR-Mutated NSCLC
Estelamari Rodriguez, MD, MPH, discusses a case study of a patient with non–small cell lung cancer harboring an EGFR L858R mutation and a TP53 mutation.
www.onclive.com
February 2, 2025 at 1:40 AM
onclive.bsky.social
Expanded Targets, Synergistic Regimens Are Needed to Propel NSCLC Beyond Anti–PD-1 Therapy #gotoPER #WLC25 #lcsm www.onclive.com/view/expande...
Expanded Targets, Synergistic Regimens Are Needed to Propel NSCLC Beyond Anti–PD-1 Therapy
Melissa L. Johnson, MD, discusses the evolution of immunotherapy approaches beyond PD-1 inhibition in lung cancer.
www.onclive.com
February 2, 2025 at 12:31 AM
onclive.bsky.social
Data Help Refine Optimal Radiotherapy Approaches in Small Cell Lung Cancer #WLC25 #lcsm #oncology www.onclive.com/view/data-he...
Data Help Refine Optimal Radiotherapy Approaches in Small Cell Lung Cancer
Walter J. Curran, MD, discusses the evolving use of radiotherapy in small cell cancer and data supporting its optimal use.
www.onclive.com
February 1, 2025 at 9:18 PM
onclive.bsky.social
We've seen lots of fascinating talks at #WLC25! Speakers have brought attention to lung cancer rates in women & nonsmokers, & multidisciplinary considerations are at the core of many conversations. Head to our site to see some of these insights! #gotoPER #lcsm
www.onclive.com/conference/w...
February 1, 2025 at 6:24 PM
onclive.bsky.social
Thanks to Russell Hales, MD, of @HopkinsMedicine for stopping by to discuss thought-provoking questions about the use of post-operative radiation therapy in lung cancer! See our site for more from the meeting! #gotoPER #WLC25 #lcsm
www.onclive.com/conference/w...
February 1, 2025 at 6:16 PM
onclive.bsky.social
Thank you to @latinamd.bsky.social, of Sylvester Comprehensive Cancer Center, for stopping by during #WLC25 to talk case-based discussions and the importance of ADCs and biomarkers in lung cancer! Check out our site for more from the meeting! #gotoPER #lcsm
www.onclive.com/conference/w...
February 1, 2025 at 4:42 PM
onclive.bsky.social
WATCH: Misty Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC. #gotoPER #WLC25 #lcsm
www.onclive.com/view/dr-shie...
Dr Shields on Key ADRIATIC Trial Data With Adjuvant Durvalumab in LS-SCLC
Misty D. Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC.
www.onclive.com
February 1, 2025 at 2:07 AM
onclive.bsky.social
Thank you to @coreylanger.bsky.social, of @pennmedicine.bsky.social, for speaking with us at #WLC25 about adjuvant NSCLC treatment! See our site for more #lcsm insights. #gotoPER
www.onclive.com/conference/w...
February 1, 2025 at 1:21 AM
onclive.bsky.social
A huge thanks to Misty Shields, MD, PhD, of Indiana University, for stopping by during #WLC25 to chat about advances in SCLC management! Check out our site for more from the meeting! #lcsm #gotoPER
www.onclive.com/conference/w...
February 1, 2025 at 1:16 AM